Leeds ECMC


The Leeds Experimental Cancer Medicine Centre (ECMC) draws on a partnership between one of the UK’s largest universities and the country’s second largest hospital trust to provide infrastructure for experimental cancer medicine studies in:

  • Early phase clinical trials (phase 1a/b) in all cancers but particularly in haematologic (B-cell) and GI malignancies. We have a particular focus on biotherapy and radiotherapy combination trials and those with pharmacokinetic and immune pharmacodynamic readouts.
  • Precision oncology components of clinical trials (phase Ib – III) with expertise in cellular, molecular and digital pathology, proteomics and genomics integrated with trial design know-how.

The Leeds ECMC works closely and synergistically with the Cancer Research UK Leeds Centre, the Leeds Institute of Clinical Trials Research (LICTR) and other members of the ECMC Network.

The ECMC Centre aims to:

  • Deliver a diverse programme of translational research bringing patient benefit.
  • Increase activity through the new Leeds Clinical Research Facility.
  • Extend our GCLP (Good Clinical Laboratory Practice) pharmacokinetic and pharmacodynamic laboratory analytical work.
  • Exploit new imaging and radiotherapy facilities.
  • Identify new biomarkers in clinical trials.

It is part of a research network of 18 Centres across the UK. These Centres are funded by Cancer Research UK, the National Institute for Health Research in England and the Departments of Health for Scotland, Wales and Northern Ireland. Each ECMC has world leading expertise within early phase clinical research. Through collaboration the ECMCs are generating new cancer treatments.

Page last updated: 26/09/2016